Name in SEC filings: Biohaven Ltd.
| Program | Event | Stage | Stated timing | Filing |
|---|---|---|---|---|
| BHV-1530 | /data readout | Stage not stated | October 2026 | 8-K · |
| Opakalim (BHV-7000) | Topline/data readout | Other | the second half of 2026 | 8-K · |
| Taldefgrobep alfa | Topline/data readout | Stage not stated | 2026 | 8-K · |
Source: ORION, orionbiotechai.com/company/BHVN, data as of Oct 13, 2026
https://www.orionbiotechai.com/company/BHVN
BHV-1530 · Topline/data readout · October 2026
SEC sources last checked .
○ Quote matched to filing (not yet reviewed by founder) · ✓ Checked by founder.
Topline/data readoutOctober 2026
Stage: Not stated
Public float: $1,044,000,000 · as of · SEC filing
New clinical data with BHV-1530, an FGFR3-directed ADC using a novel TopoIx payload, being presented at ESMO in October 2026
8-K · Filed · Last checked
Alert me · Calendar: same stage and window-end month (2026-10)
Topline/data readoutthe second half of 2026
Stage: OtherSEC filing · “Phase 2/3”
Public float: $1,044,000,000 · as of · SEC filing
Dosing remains ongoing in BHV7000-303 and topline data continues to be on timelines for the second half of 2026.
8-K · Filed · Last checked
Alert me · Calendar: same stage and window-end month (2026-12)
Topline/data readout2H 2026
Stage: Not stated
Public float: $1,044,000,000 · as of · SEC filing
Topline data expected during 2H 2026.
8-K · Filed · Last checked
Alert me · Calendar: same stage and window-end month (2026-12)
Company periods and sentences are quoted as written. A matching disclosure uses the SEC filing date for the same program and event type. As of .
| Program / event | Stated period and SEC wording | Disclosure in stated period |
|---|---|---|
| Opakalim (BHV-7000)Clinical results | the second half of 2026“Dosing remains ongoing in BHV7000-303 and topline data continues to be on timelines for the second half of 2026.” Filed · 8-K | Still within period As of Oct 19, 2026 |
| Opakalim (BHV-7000)Clinical results | 2H 2026“with topline results from the RISE3 trial expected in 2H 2026.” Filed · EX-99.1 | Not compared ORION has no confirmed start and end dates for this wording, so it is not compared with filings. |
| Opakalim (BHV-7000)Clinical results | 2H 2026“with RISE3 trial topline results expected in 2H 2026.” Filed · EX-99.1 | Not compared ORION has no confirmed start and end dates for this wording, so it is not compared with filings. |
| BHV-1530Clinical results | October 2026“New clinical data with BHV-1530, an FGFR3-directed ADC using a novel TopoIx payload, being presented at ESMO in October 2026” Filed · EX-99.1 | Still within period As of Oct 19, 2026 |
| Opakalim (BHV-7000)Clinical results | 2H 2026“pivotal readout on track for 2H 2026” Filed · EX-99.1 | Not compared ORION has no confirmed start and end dates for this wording, so it is not compared with filings. |
| Opakalim (BHV-7000)Clinical results | 2H 2026“Topline results from the Phase 2/3 RISE3 trial in focal epilepsy remain on track for 2H 2026.” Filed · EX-99.1 | Not compared ORION has no confirmed start and end dates for this wording, so it is not compared with filings. |
| Opakalim (BHV-7000)Clinical results | 2H 2026“Topline results from the Phase 2/3 RISE3 trial in focal epilepsy are expected during 2H 2026.” Filed · EX-99.1 | Not compared ORION has no confirmed start and end dates for this wording, so it is not compared with filings. |
| Opakalim (BHV-7000)Clinical results | 2H 2026“study expected in 2H 2026.” Filed · EX-99.1 | Not compared ORION has no confirmed start and end dates for this wording, so it is not compared with filings. |
| Opakalim (BHV-7000)Clinical results | the second half of 2026“We expect to report topline results from RISE 3 in the second half of 2026.” Filed · 10-Q | Still within period As of Oct 19, 2026 |
| Taldefgrobep alfaClinical results | 2H 2026“Topline data expected during 2H 2026.” Filed · EX-99.1 | Still within period As of Oct 19, 2026 |
| Opakalim (BHV-7000)Clinical results | 2H 2026“On track to receive top-line results in 2H 2026” Filed · EX-99.1 | Not compared ORION has no confirmed start and end dates for this wording, so it is not compared with filings. |
| Opakalim (BHV-7000)Clinical results | 2H 2026“Biohaven is on track to announce in 2H 2026 top-line results” Filed · EX-99.1 | Not compared ORION has no confirmed start and end dates for this wording, so it is not compared with filings. |
| Opakalim (BHV-7000)Clinical results | the second half of 2026“We expect to report topline results from RISE 3 in the second half of 2026.” Filed · 10-Q | Still within period As of Oct 19, 2026 |
| Opakalim (BHV-7000)Clinical results | 2H 2026“Pivotal epilepsy program with selective Kv7 ion channel activator, opakalim, with expected topline results in 2H 2026.” Filed · EX-99.1 | Not compared ORION has no confirmed start and end dates for this wording, so it is not compared with filings. |
| Opakalim (BHV-7000)Clinical results | the second half of 2026“In the second half of 2026, we expect to report pivotal data from our epilepsy program and topline results from our obesity program” Filed · EX-99.1 | Still within period As of Oct 19, 2026 |
| Opakalim (BHV-7000)Clinical results | 2H 2026“study expected in 2H 2026.” Filed · EX-99.1 | Not compared ORION has no confirmed start and end dates for this wording, so it is not compared with filings. |
| Taldefgrobep alfaClinical results | the second half of 2026“Topline results for the Phase 2 proof-of-concept study are expected in the second half of 2026.” Filed · 10-Q | Not compared ORION has no confirmed start and end dates for this wording, so it is not compared with filings. |
| Taldefgrobep alfaClinical results | 2H 2026“taldefgrobep alfa, completed enrollment and topline data expected in 2H 2026.” Filed · EX-99.1 | Still within period As of Oct 19, 2026 |
| Taldefgrobep alfaClinical results | the second half of 2026“In the second half of 2026, we expect to report pivotal data from our epilepsy program and topline results from our obesity program” Filed · EX-99.1 | Not compared ORION has no confirmed start and end dates for this wording, so it is not compared with filings. |
| Taldefgrobep alfaClinical results | 2H 2026“Topline data from the study are expected in 2H 2026.” Filed · EX-99.1 | Still within period As of Oct 19, 2026 |
| Taldefgrobep alfaClinical results | 2H 2026“topline results expected in 2H 2026.” Filed · EX-99.1 | Still within period As of Oct 19, 2026 |
“Not compared” means ORION has not matched this wording against a complete set of SEC filings for its period. It says nothing either way about whether a matching filing exists. Wording without exact dates is not given calendar dates.
These dated records retain their original scope and check dates.
Record BHVN-P4 · Clinical results disclosure · Window open
Last checked: .
· Checked by founder · SEC Form 10-Q
Stated period: in the second half of 2026
We expect to report topline results from RISE 3 in the second half of 2026.
· Checked by founder · SEC Exhibit 99.1
Stated period: for 2H 2026
Topline results from the Phase 2/3 RISE3 trial in focal epilepsy remain on track for 2H 2026.
· Checked by founder · Company press release
Stated period: 2H 2026
with RISE3 trial topline results expected in 2H 2026.
· Checked by founder · SEC Exhibit 99.1
Stated period: 2H 2026
with RISE3 trial topline results expected in 2H 2026.
· Checked by founder · SEC Form 8-K
Stated period: for the second half of 2026
topline data readout remains on timeline for the second half of 2026
· Checked by founder · SEC Form 8-K
Stated period: for the second half of 2026
Dosing continues in BHV7000-303 and topline data remain on track for the second half of 2026.
· Checked by founder · SEC Form 8-K
FDA partial clinical hold letter:
partial clinical hold letter on September 4, 2026
new patient enrollment only
Dosing continues
topline data remain on track
second half of 2026
Item 8.01: paragraph beginning Thus, FDA and paragraph beginning BHV7000-303, one of two pivotal studies
Company release: · Company original
Company release: · Company original
Company press release listing · checked
The initial entry means the earliest wording located within the sources checked; an exhaustive history is not asserted.
Company timing wording is retained. A newer corporate release about another program does not establish a results announcement for this trial.
Additional source review: 2026-10-10. Earlier retained sources were reviewed on 2026-10-09; their original source-check dates and scopes are retained.
ClinicalTrials.gov NCT06309966: acronym RISE 3; organization study ID BHV7000-303.
SEC filings searched through : 10-Q 5/4, 8/10, 8-K 8/26 quotes checked against originals. Later SEC filings not searched. Supplement reviewed 2026-10-10: selected 2026-09-10 SEC Form 8-K timing occurrences. This is not an exhaustive later-filing search.
Company press releases checked : Company press releases page 1 checked on 10/9; Oct 8 release is BHV-1300, not RISE3.
Checked by founder: .
· Display rule corrected — equivalent timing phrases (e.g., 'H2 2026' / 'second half of 2026') are now shown as Statement retained. Source quotes and status unchanged. · Equivalent timing notation is compared after normalization. · Founder approved the normalization correction and this exact public line in this chat on 2026-10-09.
· Added source-context excerpts from 2026-09-10 SEC Form 8-K. · Founder-requested context retained from the checked original filing. · https://www.sec.gov/Archives/edgar/data/1935979/000193597926000077/bhvn-20260904.htm
· Added previously omitted 2026-09-10 SEC Form 8-K timing source. · Selected-source supplement following founder review; prior rows retained. · https://www.sec.gov/Archives/edgar/data/1935979/000193597926000077/bhvn-20260904.htm
Biohaven (BHVN) — opakalim / RISE3 focal epilepsy · Topline results: “in the second half of 2026” (SEC Form 10-Q 2026-05-04); statement retained “for 2H 2026” (2026-08-10); statement retained “2H 2026” (2026-08-26); statement retained “2H 2026” (2026-08-26); statement retained “for the second half of 2026” (2026-09-10); statement retained “for the second half of 2026” (2026-09-10). Status Window open, checked 2026-10-10. Sources: https://www.sec.gov/Archives/edgar/data/1935979/000193597926000045/bhvn-20260331.htm | https://www.sec.gov/Archives/edgar/data/1935979/000193597926000067/a2026q2bhvnearningsprex991.htm | https://ir.biohaven.com/news-releases/news-release-details/biohaven-and-sk-biopharmaceuticals-enter-strategic-global | https://www.sec.gov/Archives/edgar/data/1935979/000193597926000072/exhibit991-biohavenandskbi.htm | https://www.sec.gov/Archives/edgar/data/1935979/000193597926000077/bhvn-20260904.htm | https://www.sec.gov/Archives/edgar/data/1935979/000193597926000077/bhvn-20260904.htm
Dosing continues in BHV7000-303 and topline data remain on track for the second half of 2026.
Suggest an SEC timing statement to add for BHVN. You can include the original filing link in your note. The founder reads each request by hand.
Or email ORION.
See BHVN in the calendar · Review labels and methodology